Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC - Trial NCT06361758
Access comprehensive clinical trial information for NCT06361758 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Zhongshan Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Zhongshan Hospital
Timeline & Enrollment
Phase 2
May 31, 2024
May 31, 2027
Primary Outcome
Objective Response Rate (ORR) per RECIST v1.1
Summary
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and
 safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with
 advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of
 immunotheray and antiangiogenic therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06361758
Non-Device Trial